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Available online 10 December 2015Aims: Acotiamide is the ﬁrst-in-class drug for the treatment of functional dyspepsia. Although pharmacological
and therapeutic actions of acotiamide are thought to be derived from its inhibitory effects on acetylcholinesterase
(AChE),whether the concentration of acotiamide at the site of action is sufﬁcient to inhibit AChE remains unclear.
Since major site of acotiamide action is thought to be the cholinergic nerve terminals in gastricmyenteric plexus,
we studied the distribution of [14C]acotiamide into gastric myenteric plexus.
Main methods: Distribution of [14C]acotiamide was evaluated using macro- and micro-autoradiography in rats
and dogs.
Key ﬁndings: The results of macro-autoradiography showed the concentration of radioactivity was 27.9 μM in rat
stomach, which was 12 times higher than IC50 of acotiamide for rat AChE. Being different from rats, the distribu-
tion of radioactivity in themuscular layerwas distinguishable from that in themucosal layer in dog stomach. The
concentration of radioactivity in the muscular layer of dog stomach (1.41 μM) was approximately two-times
lower than those in the mucosal layer, however, it was approximately 1.2 times higher than IC50 of acotiamide
for dog AChE. The results of micro-autoradiography also showed the radioactivity distributed homogenously in
themuscular layer of rat stomach, suggesting the concentration of radioactivity around the ganglion ofmyenteric
plexus is similar to that in the muscular layer of stomach.
Signiﬁcance: These ﬁndings suggest acotiamide distributes to themyenteric plexus of stomach, a putative site of
acotiamide action, with adequate concentrations to inhibit AChE, in both of rat and dog stomachs.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Acetylcholinesterase1. Introduction
Functional dyspepsia (FD) is a common gastrointestinal disorder de-
ﬁned as symptom-based conditions in the absence of organic disease
[1]. Symptoms are categorized as postprandial distress and epigastric
pain syndromes, which are associated with impaired gastric accommo-
dation and emptying [2,3]. Gastric accommodation and emptying are
induced by coordinating motility of gastric fundus, body and antrum,
which are regulated by complex nervous systems including cholinergic
neurons projected from dorsal motor nucleus of the vagus to the stom-
ach [4,5].
Acotiamide is the ﬁrst-in-class drug for the treatment of FD [6]. Al-
though some clinical studies have suggested that proton pump inhibi-
tors (e.g., omeprazole) and prokinetics (e.g., itopride or mosapride) areri, Kumagaya-shi, Saitama 360-
ii).
. This is an open access article undereffective, no product except for acotiamide has gotten marketing ap-
proval for the treatment of patients with FD [6]. Clinical studies have
shown that acotiamide enhances the gastric accommodation reﬂex
and gastric emptying rate [7] and improves meal-related symptoms
such as postprandial fullness, upper abdominal bloating and early satia-
tion in patients of FD [8]. These pharmacological and therapeutic effects
of acotiamide are thought to be derived from its inhibitory effects on
acetylcholinesterase (AChE) which results in the potentiation choliner-
gic neurons [9,10]. In fact, an in vitro animal experiment showed that
acotiamide enhanced acetylcholine (ACh)-induced but not carbachol
(not hydrolyzed by AChE)-induced contraction of isolated gastric an-
trum strips of guinea pig [10]. In addition, an in vivo animal experiment
showed that acotiamide enhanced gastric body contractions induced by
electrical stimulation of the vagus nerve in rats, which were completely
abolished by classical antagonist of ACh receptors [11].
Acotiamide inhibits AChE with half maximal inhibitory concentra-
tions (IC50) of 3.0, 2.3 and 1.2 μM for human recombinant, and rat and
canine gastric AChEs, respectively [10,11]. These values aremuch largerthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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acotiamide is concentrated into the stomach tissue by carrier-mediated
uptake processes, which may account for the selective action of
acotiamide for gastric smooth muscle but not for skeletal muscle and
central nervous system in rats [12].
Myenteric plexus is a mesh-like system of neurons which provide
majormotor innervation to the gastrointestinalmuscles [13]. Therefore,
main target of acotiamide action is thought to be AChE localized around
the cholinergic nerve terminals in themyenteric plexuswhich is located
in the muscular layer of the stomach. However, whether sufﬁcient con-
centrations of acotiamide are attained in the myenteric plexus of the
stomach to inhibit AChE, has not been conﬁrmed in any species yet, al-
though the total concentrations of acotiamide in the homogenate of rat
stomach after in vivo administration were reported to be higher than
in vitro IC50 value of acotiamide estimated from rat gastric AChE [11].
The aim of the present study was to examine the distribution of
acotiamide into the myenteric plexus of the stomach after [-
14C]acotiamide dose enough to exhibit pharmacological action, using
macro- and micro-autoradiographs, and to estimate whether the sufﬁ-
cient concentration of acotiamide is attained in the myenteric plexus of
the stomach, a putative site of acotiamide action, to inhibit AChE in rat
and dog stomachs.
2. Materials and methods
2.1. Chemicals
N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-
dimethoxybenzoyl)amino]thiazole-4-carboxamide
monohydrochloride trihydrate (acotiamide hydrochloride, Z-338/
YM443, Fig. 1) was synthesized in the central research laboratories of
Zeria Pharmaceutical Co., Ltd. (Saitama, Japan). [14C]Acotiamide (2.26
GBq/mmol) was synthesized by GE Healthcare UK Ltd. (Buckingham-
shire, England). All other chemicals were of reagent grade.
2.2. Animals
Male Sprague–Dawley rats aged six to seven weeks were obtained
from Charles River Japan, Inc. (Kanagawa, Japan) and housed under
standard controlled environmental conditions at 23 ± 3 °C and 55 ±
20% humidity with a 12-h light/dark cycle, and food (CRF-1; Oriental
Yeast Co., Ltd., Tokyo, Japan or CE-2; CLEA Japan Inc., Tokyo, Japan)
andwater available ad libitum. Ratswere allowed to acclimate to labora-
tory conditions for at least one week prior to experiments.
Male beagle dogswere obtained fromOriental Yeast Co., Ltd. (Tokyo,
Japan) or the Institute for Animal Reproduction (Ibaraki, Japan) and
housed individually in experimental cages where they were acclimated
for at least 12 days before entry to the study. Laboratory chow (NVE-10,
Nihon Pet Food K.K., Tokyo, Japan; or DS-A, Oriental Yeast Co., Ltd.) was
provided once daily andwaterwas given ad libitum. Animalswerehoused
under standard controlled environmental conditions at 22 ± 3 °C and
50 ± 20% humidity with a 12-h light/dark cycle.Fig. 1. Structure of acotiamide hydrochloride.All animal experiments were approved by the Animal Care and Use
Committee of the Central Research Laboratories of Zeria Pharmaceutical
Co., Ltd., Animal Ethical Committee, Tsukuba Laboratories, Nemoto Sci-
ence Co., Ltd. (Ibaraki, Japan) and the Institutional Animal Care and Use
Committee of Shin Nippon Biomedical Laboratories, Ltd. (Wakayama,
Japan).
2.3. AChE staining of rat stomach
Rats were exsanguinated via the abdominal aorta under anesthesia
with diethyl ether and the stomachwas excised, washed with saline, li-
gated at the pylorus, ﬁlled with OCT compound through the cardia, li-
gated at the cardia. Stomach was embedded with OCT compound and
frozen in a bath of isopentane and dry ice. Embedded stomach was cut
into 6-μm-thick sections using a cryomacrocut CM1900, and immersed
in 3 mM copper sulfate/0.05 mM potassium ferricyanide solution con-
taining acetylthiocholine iodide at 37 °C for 90 min. After rinsing in dis-
tilledwater, sectionswere immersed inMayer's hematoxylin for 10min
and then washed with running tap water, dehydrated in ethyl alcohol,
and immersed in xylene.
2.4. AChE staining of dog stomach
Dogs were euthanized by intravenous administration of sodium
pentobarbital and supersaturated potassium chloride solutions. Stom-
achwas immediately excised, and divided into 2 pieces along the great-
er curvature. The pieces were rinsed with physiological saline and
divided into approximately 1.5 cm×1.5 cmsections and frozen in liquid
nitrogen. Sections were embedded with an OCT compound and frozen
in hexane and dry ice. The frozen serial sections were prepared as 8-
μm sections using a cryomacrocut CM1900. The sections were im-
mersed as described in AChE staining of stomachs of rats.
2.5. Macro-autoradiography of rat stomach
As any pharmacological effects haven't been reported after oral ad-
ministration of acotiamide to rats although acotiamide is orally admin-
istered for the treatment of FD, rats were subcutaneously administered
with [14C]acotiamide (30mg and 20.6MBq/kg). These dose and route of
acotiamide administration were reported to increase the gastric motili-
ty index signiﬁcantly until 90 min after the administration to rats [11].
Rats were exsanguinated via the abdominal aorta under anesthesia
with diethyl ether, and the stomach was excised at 30min after the ad-
ministration of acotiamide. The excised stomach was washed with sa-
line, ligated at the pylorus, ﬁlled with 2% CMC-Na through the cardia,
ligated at the cardia, embedded with 2% CMC-Na and frozen in a hex-
ane/dry ice bath. The embedded stomach was cut into 40-μm-thick sec-
tions using a cryomicrotome CM3600 (Leica Microsystems GmbH,
Wetzlar, Germany). Sections were exposed by contact with an
Imaging-Plate BAS-III2040 (Fuji Photo Film, Tokyo, Japan) in a shield
box for 16 h. After exposure, the Imaging-Plate was analyzed with a
Bio-Imaging Analyzer BAS-2000 (Fuji Photo Film, Tokyo, Japan) to ob-
tain macro-autoradioluminograms and measure radioactivities in the
tissues. The concentration of the radioactivity in the tissue was quanti-
ﬁed by the absolute calibration method [14,15,16,17]. The calibration
curve through the origin (Y = aX) was prepared based on the mean
value of the intensity of luminescence (PSL-BG/mm2) of the blood si-
multaneously collectedwhen stomachwas removed and blood concen-
tration of acotiamide determined by a liquid scintillation analyzer LSC-
6100 (Aloka, Tokyo, Japan). The background (BG) value was calculated
as the mean value of the intensity of luminescence in three positions
on the rim of the section. The lower limit of quantiﬁcation was deﬁned
as twice the BG value. Tissue concentration of acotiamide (mean ±
standard deviation) was expressed as μM based on the assumption
that tissue speciﬁc gravity equals 1 mL/g.
Fig. 2. Photomicrograph of AChE activity staining for the muscular layer of rat stomach.
The stomach was embedded with OCT compound. Embedded stomach was cut into 6-
μm-thick sections and immersed in 3 mM copper sulfate/0.05mM potassium ferricyanide
solution containing acetylthiocholine iodide at 37 °C for 90 min. Then, sections were im-
mersed in Mayer's hematoxylin, dehydrated in ethyl alcohol, and immersed in xylene.
Scale bar represents 20 μm. Arrow in photomicrograph indicates nerve cells, and brownish
site indicates AChE activity staining located between the circular (C) and longitudinal
(L) muscles.
Fig. 3. Photomicrograph of AChE activity staining for the muscular layer of dog stomach.
The stomach was embedded with OCT compound. Embedded stomach was cut into 8-
μm sections and immersed as described in AChE staining of rat stomach. Scale bar repre-
sents 100 μm. Arrow in photomicrograph indicates the ganglia, and brownish site indi-
cates AChE activity staining.
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Dogs were anesthetized with medetomidine and isoﬂurane, and
subjected to abdominal incision. A catheter was inserted into the duo-
denum from an incision and [14C]acotiamide (30 mg and 1 MBq/kg)
was administered. These dose and route of acotiamide administration
were reported to increase the gastric motility index signiﬁcantly at
least until 30 min after the administration to dogs [18]. Dogs were eu-
thanized by intravenous administration of 64.8 mg/mL sodium pento-
barbital solution (2 mL/kg) at 30 min after dosing. The cardia of the
stomachwas tiedwith a silk suture and the stomachwas promptly enu-
cleated. The excised stomachwas washed with saline and ligated at the
pylorus. The stomach was embedded with 5% CMC-Na and frozen in a
bath of hexane and dry ice. The embedded stomach was cut into 30-
μm-thick sections using a cryomicrotomeCM3600,whichwere exposed
by contact with an Imaging-Plate BAS-MS2040 in a shield box for 16 h.
After exposure, the Imaging Plate was analyzed with the Bio-Imaging
Analyzer BAS-2500 (Fuji Photo Film, Tokyo, Japan) to obtain macro-
autoradioluminograms and measure radioactivities in the tissues. The
concentration of the radioactivity in the tissuewas quantiﬁed by the ab-
solute calibrationmethod as described in macro-autoradiography of rat
stomach. Tissue concentration of acotiamide (mean ± standard devia-
tion) was expressed as μM based on the assumption that tissue speciﬁc
gravity equals 1 mL/g.
2.7. Nissl staining and micro-autoradiography of rat stomach
Ratswere treatedwith [14C]acotiamide and the stomachwas excised
as described inmacro-autoradiography of rat stomach. Excised stomach
was washed with saline, immersed in 10% formalin, and then placed in
gumsucrose solution. Once complete submersionwas conﬁrmed, stom-
ach was ligated at the pylorus, ﬁlled with OCT compound through the
cardia, ligated at the cardia, embedded with an OCT compound and fro-
zen in liquid nitrogen. Serial sections of 6-μm-thick were obtained with
a cryomacrocut CM1900 (LeicaMicrosystemsGmbH)and attached onto
MAS-coated glass slides (Matsunami Trading Co., Ltd., Osaka, Japan)
coveredwith emulsion for themicro-autography andwithout emulsion
for Nissl staining. For Nissl staining, sections were dehydrated in etha-
nol, rehydrated in distilled water and submerged in 0.1% cresyl violet
solution for approximately 30 min until the desired depth of staining
was achieved. Sections were dehydrated in ethanol, immersed in xy-
lene, and covered with a coverslip. For the micro-autoradiography, sec-
tionswere set in a slide glass case and dried completely, then exposed in
a refrigerator at 4 °C for 2 weeks. Sections were developed, subjected to
hematoxylin and eosin staining, and ﬁnally covered with a coverslip.
3. Results and discussion
Although the localization of AChE in the muscular layer of the stom-
ach has been reported for humans [19], little information is available on
the experimental animals. Therefore, we studied the localization of
AChE in themuscular layer of rat and dog stomachs usingAChE staining.
As shown in the Fig. 2, AChE-activity was detected around the nerve
cells in the muscular layer of the rat stomach, which were located be-
tween the circular and longitudinal muscles, indicating that the nerve
cells are components of the myenteric plexus. Similarly, AChE-activity
was also found in the ganglia of themyenteric plexus of the dog stomach
(Fig. 3). These ﬁndings are consistent with those of humans [19], and
suggest that major target of acotiamide action in rats and dogs is AChE
in the ganglia of myenteric plexus located in the muscular layer of the
stomach.
Macro-autoradiograms of rat and dog stomachs after the adminis-
tration of [14C]acotiamide are shown in Figs. 4 and 5, respectively. The
autoradiograms of rat and dog stomachs showed no marked difference
of the radioactivity between the stomach sections. Themean concentra-
tion of acotiamide in the stomach of rats estimated from theradioactivity was 27.9 ± 10.4 μM (n = 3), which was 12 times higher
than IC50 of acotiamide (2.3 μM) estimated from an in vitro experiment
using rat gastric AChE [11]. Althoughmucosal andmuscular layers were
not distinguishable in the rat stomach (Fig. 4), they were distinguished
in the dog stomach (Fig.5). The mean concentration of radioactivity in
themuscular layer of the dog stomach (1.41± 0.18 μM, n= 3)was ap-
proximately two-times lower than that of mucosal layer (3.24 ±
0.66 μM, n = 3), however, it was approximately 1.2 times higher than
IC50 of acotiamide (1.2 μM) estimated from an in vitro experiment
using dog gastric AChE [10].
Nissl stained and micro-autoradiographic images of the muscular
layer in the rat stomach are shown in Fig. 6A and B, respectively. As
shown in the Fig.6A, Nissl stain clearly visualized nerve cells of
myenteric plexus in the muscular layers of rat stomach. Micro-
Fig. 4.Macro-autoradiogram of rat stomach. Thirty mg/kg of [14C]acotiamide (20.6MBq/kg)
were administered subcutaneously to rats and the stomach was excised at 30 min after
the administration. The excised stomach was embedded with 2% CMC-Na, sliced into
40-μm-thick sections, exposed to imaging plate for 16 h and analyzed with imaging
analyzer.
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homogenously in the muscular layer (the radioactivity was detected
as black-silver grains) and distribution of the radioactivity was not ap-
parently different between the surrounding of nerve cells and other re-
gions of muscular layer of rat stomach (Fig. 6B). The results suggest that
the concentration of radioactivity around the ganglion of themyenteric
plexus is similar to that in themuscular layer of the rat stomach. Howev-
er, in the case of rats, the result of the macro-autoradiography showed
that the muscular layer could not be distinguished from mucosal layer
(Fig. 4) probably due to the thinness of the rat gastric wall. Thus, it
may be impossible to estimate the concentrations of radioactivity di-
rectly from the macro-autoradiography. Nonetheless, assuming the dif-
ference in the concentrations of acotiamide between muscular and
mucosal layers found in dog stomach is similar to that in rat stomach,
the concentrations of radioactivity in the muscular layer of rat stomach
are estimated to be 8.5 μM, which was still much higher than IC50 of
acotiamide (2.3 μM) estimated from an in vitro experiment using ratFig. 5.Macro-autoradiogram of dog stomach. Thirty mg/kg of [14C]acotiamide (1 MBq/kg) wer
administration. The stomach was embedded with 5% CMC-Na, sliced into 30-μm-thick sectionsgastric AChE [11]. On the other hand, in the case of dogs, the concentra-
tions of radioactivity in the muscular layer could be directly estimated
from macro-autoradiography, therefore the concentrations of radioac-
tivity around the ganglion of the myenteric plexus would be identical
to those estimated frommacro-autoradiography (1.41 μM). The concen-
trationwas higher than IC50 of acotiamide for dog gastric AChE (1.2 μM)
[10], as described above. These ﬁndings suggest that adequate amount
of acotiamide could distribute into the ganglion of themyenteric plexus
of the stomach to inhibit AChE in both of the rat and dog stomachs.
Finally, it should be notiﬁed that radioactivity is not always identical
to acotiamide but can be metabolites of acotiamide or the mixture of
acotiamide and its metabolites. Although we do not have direct evi-
dence that radioactivity in the stomach mainly represents unchanged
acotiamide, the concentration of acotiamide in the homogenate of rat
stomach determined by high performance liquid chromatography re-
ported previously [11] is not so different from the concentration of the
radioactivity in the rat stomach found in the present study. Thus, the ra-
dioactivity found in the rat stomach is considered to be mainly un-
changed acotiamde. In the case of dogs, the concentration of
acotiamide in the homogenate of stomach has not been reported. How-
ever, plasma concentration-time proﬁles of acotiamide and radioactive
acotiamide after the administration of the same dose of acotiamide as
the present study to dogs indicate that plasma concentration of un-
changed acotiamide at 30min (equal to the sampling time of dog stom-
ach in the present study) after the oral administration is almost identical
to that of radioactivity at 30 min after the oral administration of the
same dose of [14C]acotiamide to dogs (Yoshii et al., unpublished obser-
vation). The ﬁndings suggest that radioactivity mainly represents un-
changed acotiamide at least in plasma at 30 min after the
administration of [14C]acotiamide. The ﬁndings also suggest that
acotiamide is not extensively metabolized at 30 min and unchanged
acotiamide appears to predominantly distribute into the stomach at
30 min after the oral administration to dogs. Thus, the radioactivity
found in the dog stomach is also considered to be mainly unchanged
acotiamide.
4. Conclusions
The results of the present study showed that the radioactivity dis-
tributes into the myenteric plexus, a putative site of acotiamide action,
in the muscular layer of the rat and dog stomachs, and that thee administered intra-duodenally to dogs and the stomach was excised at 30 min after the
, exposed to imaging plate for 16 h and analyzed with imaging analyzer.
Fig. 6.Nissl-stained photomicrograph (A) andmicro-autoradiogram (B) of the rat stomach. Thirtymg/kg of [14C]acotiamide (20.6MBq/kg)were administered subcutaneously to rats and
the stomach was excised at 30min after the administration. The stomachwas embeddedwith OCT compound. Embedded stomach was cut into 6-μm-thick sections. Serial sections were
attached onto glass slides covered with emulsion for themicro-autography andwithout emulsion for Nissl staining. For Nissl staining, sectionswere dehydrated in ethanol, rehydrated in
distilled water and submerged in 0.1% cresyl violet solution for approximately 30 min. Sections were dehydrated in ethanol, immersed in xylene, and covered with a coverslip. For the
micro-autoradiography, sections were dried completely, then exposed in a refrigerator at 4 °C for 2 weeks. Sections were developed, subjected to hematoxylin and eosin staining, and ﬁ-
nally covered with a coverslip. Scale bars represent 20 μm. The red arrows indicate nerve cells.
97K. Yoshii et al. / Life Sciences 145 (2016) 93–97concentrations of radioactivity around themyenteric plexus are estimat-
ed to be adequate to inhibit AChE in rats and dogs. Since the dose of
acotiamide used in the present study was enough to exhibit pharmaco-
logical action in rats and dogs [11,18], the present ﬁndings suggest that
inhibition of gastric AChE is amajormechanismof action responsible for
the pharmacological effects of acotiamide on the gastrointestinal tract of
rats and dogs, and may be for the therapeutic effects on the symptoms
of patients with FD.
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